Otello Stampacchia bought $8.0M of IMA
director at ImageneBio, Inc.. 267,556 shares at an average of $29.90, traded Jul 25, 2025, filed Jul 30, 2025.
Score components
- +15RoleDirector
- +25Trade size$8.0M at market
- +10Relative to holdingsHoldings up 143%
- 0Price contextNo price history yet
- +8Cluster2 insiders buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -12.4%, 3m -42.5%, 6m -51.7%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001415889-25-020598, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jul 25, 2025 | MOption exercise Common Stock | +379 | - | - | 379 | Jul 30, 2025 |
| Jul 25, 2025 | POpen-market purchase Common Stockindirect: Omega Fund VI, L.P. | +267,556 | $29.90 | $8.0M | 454,982 | Jul 30, 2025 |
| Jul 25, 2025 | MOption exercise Stock Option (right to buy)derivative | -17,520 | $0.00 | $0 | 0 | Jul 30, 2025 |
Related signals
Other insiders at ImageneBio, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 33Weak | IMAbuy ImageneBio, Inc. | Joseph P Slattery director | $96k 16,000 shares | - | |
| 54Moderate | ImageneBio, Inc. | David P Bonita director | $2.5M 83,611 shares | +41% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.